

# Hideaki Ijichi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3534896/hideaki-ijichi-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105  
papers

3,990  
citations

37  
h-index

60  
g-index

137  
ext. papers

4,484  
ext. citations

6.3  
avg, IF

4.84  
L-index

#	Paper	IF	Citations
105	Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. <i>Genes and Development</i> , <b>2006</b> , 20, 3147-60	12.6	285
104	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. <i>Cancer Science</i> , <b>2012</b> , 103, 670-6	6.9	212
103	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1979	59.2	212
102	Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4106-17	15.9	191
101	Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. <i>Cancer Research</i> , <b>2005</b> , 65, 5864-71	10.1	162
100	Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1644-8	8.7	121
99	Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. <i>Cancer Research</i> , <b>2003</b> , 63, 8132-7	10.1	106
98	Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. <i>Hepatology</i> , <b>2004</b> , 40, 243-51	11.2	104
97	Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. <i>Molecular Carcinogenesis</i> , <b>2009</b> , 48, 703-12	5	90
96	Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 1090-5	11.5	83
95	Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. <i>Gastroenterology</i> , <b>2020</b> , 158, 226-237.e5	13.3	80
94	Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 318, 461-9	3.4	78
93	The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. <i>Oncogene</i> , <b>2006</b> , 25, 633-42	9.2	77
92	p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. <i>Cancer Research</i> , <b>2005</b> , 65, 10822-9	10.1	77
91	Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. <i>Gastroenterology</i> , <b>2009</b> , 136, 206-16	13.3	71
90	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPβ. <i>Carcinogenesis</i> , <b>2014</b> , 35, 2404-14	4.6	70
89	Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. <i>Oncogene</i> , <b>2004</b> , 23, 1043-51	9.2	69

88	Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. <i>Oncogene</i> , <b>2005</b> , 24, 662-71	9.2	69
87	Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 203-13	6.9	63
86	Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. <i>Cancer Research</i> , <b>2004</b> , 64, 3428-35	10.1	61
85	Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 289, 350-7	3.4	56
84	Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 394, 1042-6	3.4	54
83	Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E3806-E3815	11.5	49
82	Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. <i>Gastroenterology</i> , <b>2010</b> , 138, 1055-67.e1-4	13.3	49
81	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 61469-61484	3.3	49
80	Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2173-83	12.9	48
79	Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. <i>Pancreas</i> , <b>2013</b> , 42, 202-8	2.6	47
78	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1400-8	13.4	47
77	Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. <i>Gut</i> , <b>2011</b> , 60, 1249-53	19.2	47
76	Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. <i>Japanese Journal of Cancer Research</i> , <b>2002</b> , 93, 1213-20		45
75	Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment. <i>Oncogenesis</i> , <b>2019</b> , 8, 8	6.6	43
74	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. <i>Scientific Reports</i> , <b>2016</b> , 6, 23899	4.9	43
73	Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. <i>Nucleic Acids Research</i> , <b>2005</b> , 33, e131	20.1	40
72	Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. <i>Cancer Research</i> , <b>2013</b> , 73, 2221-34	10.1	39
71	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1294-9	4.3	38

70	Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. <i>Carcinogenesis</i> , <b>2013</b> , 34, 2380-8	4.6	38
69	Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. <i>Biochemical and Biophysical Research Communications</i> , <b>2012</b> , 419, 32-7	3.4	37
68	Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 238-46	6.9	36
67	Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. <i>Cancer Science</i> , <b>2013</b> , 104, 337-44	6.9	33
66	Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40, 774-80	2.8	33
65	Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. <i>Journal of Biochemistry</i> , <b>2007</b> , 141, 345-51	3.1	33
64	Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 318, 289-96	3.4	32
63	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. <i>Oncogene</i> , <b>2017</b> , 36, 6262-6271	9.2	31
62	Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 4185-4194	5.4	30
61	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. <i>Cancer Science</i> , <b>2012</b> , 103, 1489-92	6.9	29
60	Photoacoustic tomography of human hepatic malignancies using intraoperative indocyanine green fluorescence imaging. <i>PLoS ONE</i> , <b>2014</b> , 9, e112667	3.7	29
59	Impact of S-1 on the survival of patients with advanced pancreatic cancer. <i>Pancreas</i> , <b>2010</b> , 39, 989-93	2.6	27
58	Prevalence of Pancreatic Cystic Lesions Is Associated With Diabetes Mellitus and Obesity: An Analysis of 5296 Individuals Who Underwent a Preventive Medical Examination. <i>Pancreas</i> , <b>2017</b> , 46, 801-805	2.6	25
57	Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1. <i>Nature Communications</i> , <b>2016</b> , 7, 13006	17.4	25
56	Pancreatic cancer with malignant ascites: clinical features and outcomes. <i>Pancreas</i> , <b>2015</b> , 44, 380-5	2.6	25
55	A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. <i>Oncology</i> , <b>2009</b> , 77, 300-3	3.6	25
54	Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. <i>Pancreas</i> , <b>2013</b> , 42, 687-91	2.6	24
53	TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4603-13	5.3	22

52	Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 195-202	2.5	21
51	Frameshift mutations at mononucleotide repeats in RAD50 recombinational DNA repair gene in colorectal cancers with microsatellite instability. <i>Japanese Journal of Cancer Research</i> , <b>2001</b> , 92, 587-91		20
50	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 85-92	3.5	19
49	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 158-63	2.5	19
48	Reduced expression of RAS protein activator like-1 in gastric cancer. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 1293-302	7.5	18
47	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. <i>Journal of Gastrointestinal Cancer</i> , <b>2014</b> , 45, 307-11	1.6	17
46	Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. <i>Oncogenesis</i> , <b>2016</b> , 5, e277	6.6	16
45	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 933-9	4.9	15
44	Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. <i>Pancreas</i> , <b>2014</b> , 43, 1014-7	2.6	15
43	Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. <i>Oncolmmunology</i> , <b>2012</b> , 1, 569-571	7.2	15
42	Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. <i>Cancer Genetics and Cytogenetics</i> , <b>2004</b> , 149, 68-71		15
41	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1291-7	3.5	14
40	Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. <i>Pancreatology</i> , <b>2013</b> , 13, 285-9	3.8	14
39	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. <i>Laboratory Investigation</i> , <b>2012</b> , 92, 1161-70	5.9	14
38	Runx3 interacts with DNA repair protein Ku70. <i>Experimental Cell Research</i> , <b>2007</b> , 313, 3251-60	4.2	14
37	Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. <i>Scientific Reports</i> , <b>2018</b> , 8, 6150	4.9	13
36	TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2237-46	7.5	13
35	Disease-specific mortality among patients with intraductal papillary mucinous neoplasm of the pancreas. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 486-91	6.9	12

34	False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma. <i>British Journal of Radiology</i> , <b>2002</b> , 75, 548-51	3.4	12
33	Fuel economy of multigrade gear lubricants. <i>Industrial Lubrication and Tribology</i> , <b>2000</b> , 52, 165-173	1.3	12
32	A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 711-21	6.9	11
31	Indirubin 3SOxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. <i>Translational Oncology</i> , <b>2019</b> , 12, 1574-1582	4.9	11
30	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 985-90	3.5	11
29	Abstract 4383: Targeting tumor microenvironment with gemcitabine is useful for the treatment of pancreatic ductal adenocarcinoma <b>2012</b> ,		11
28	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. <i>Scientific Reports</i> , <b>2019</b> , 9, 18859	4.9	11
27	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 99	9.8	11
26	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. <i>Cancer Science</i> , <b>2018</b> , 109, 3602-3610	6.9	11
25	Adhesive Interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease. <i>Journal of Crohnts and Colitis</i> , <b>2018</b> , 12, 1219-1231	1.5	11
24	Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism. <i>Gut</i> , <b>2021</b> , 70, 1713-1723	19.2	10
23	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. <i>Medical Oncology</i> , <b>2018</b> , 35, 100	3.7	8
22	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 911-5	3.5	7
21	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 21194	4.9	7
20	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. <i>Cancer Genomics and Proteomics</i> , <b>2020</b> , 17, 695-705	3.3	6
19	Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 5455-9	5.6	5
18	Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. <i>Pain</i> , <b>2020</b> , 161, 2909-2919	8	5
17	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 338-344	4.3	5

16	Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. <i>Pancreatology</i> , <b>2019</b> , 19, 695-698	3.8	4
15	Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 2210-21	6.1	3
14	No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer. <i>Anticancer Research</i> , <b>2016</b> , 36, 4965-70	2.3	3
13	Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 4792-4798	5.9	3
12	Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma.. <i>British Journal of Anaesthesia</i> , <b>2022</b> ,	5.4	2
11	Effect of home enteral nutrition after pancreaticoduodenectomy. <i>Nutrition</i> , <b>2019</b> , 60, 206-211	4.8	2
10	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 605-613	4.3	2
9	Inhibition of transforming growth factor- $\beta$ signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndrome. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239908	3.7	1
8	ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1020-1028	4	1
7	Late-Evening Carbohydrate and Branched-Chain Amino Acid Snacks Improve the Nutritional Status of Patients Undergoing Hepatectomy Based on Bioelectrical Impedance Analysis of Body Composition. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 81-91	1.3	1
6	Which patients benefit from the inhibition of renin-angiotensin system in advanced pancreatic cancer? An exploratory analysis in 349 patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15216-e15216	2.2	
5	Genetically-engineered mouse pancreatic cancer models. <i>Suizo</i> , <b>2010</b> , 25, 28-34	0.1	
4	Effect of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 309-309	2.2	
3	A retrospective analysis of early CA19-9 progression in salvage-chemotherapy for refractory pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15146-e15146	2.2	
2	A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 290-290	2.2	
1	Associations between K-ras mutation, smoking, and prognosis of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 298-298	2.2	